BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial
Phase 3negativeKrazaticetuximabNegative
AI Analysis
Summary
Bristol Myers Squibb's Krazati combined with cetuximab failed its confirmatory Phase 3 colorectal cancer trial, showing shorter median overall and progression-free survival compared to chemotherapy controls.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Krazati in combination with cetuximab showed shorter median overall and progression-free survival compared to chemotherapy control arm
Importance:8/10
Sentiment:
-0.90
Phase 3 failureoncologycolorectal cancercombination therapynegative trial data
Related Companies
Read the original article
Published by BioSpace on July 7, 2026 12:05 PM